The present invention relates to novel compounds that are photo-crosslinked by visible light and spatiotemporal proximity photo-crosslinking by visible light activation (spotlight) using the same. When a target nucleic acid or target protein is bound to the novel compounds by the property of being photo-crosslinked to the proximal protein or peptide by irradiation with visible light and it is irradiated with visible light, the novel compounds according to the present invention can be photo-crosslinked with a protein or peptide that physically interacts with the target protein or target nucleic acid, and thus, there are advantages in that it is possible to overcome diffusive labeling, which is a limitation of the conventional proximity labeling technology, by photo-crosslinking by visible light irradiation, which is a safe method for a living body, and to improve the accuracy of protein interactome identification.

An organic light-emitting display apparatus includes a substrate, an organic light-emitting device disposed above the substrate, and an encapsulation unit disposed above the organic light-emitting device and sealing the organic light-emitting device, wherein the encapsulation unit includes a compound represented by Formula 1.

[R.sub.1-(L.sub.1).sub.a1].sub.b1-(Ar.sub.1).sub.c1-[(L.sub.2).sub.a2-R.sub.2].sub.b2.Formula 1

An organic light-emitting display apparatus includes a substrate, an organic light-emitting device disposed above the substrate, and an encapsulation unit disposed above the organic light-emitting device and sealing the organic light-emitting device, wherein the encapsulation unit includes a compound represented by Formula 1.

[R.sub.1-(L.sub.1).sub.a1].sub.b1-(Ar.sub.1).sub.c1-[(L.sub.2).sub.a2-R.sub.2].sub.b2.Formula 1

Disclosed herein is a compound for use in a composition applied to a blood vessel, wherein the compound softens and/or disrupts the crystalline matrix of calcified plaque. Methods of treatment comprising applying the disclosed composition are also disclosed. Plaque-softening compounds are also disclosed.

Disclosed herein is a compound for use in a composition applied to a blood vessel, wherein the compound softens and/or disrupts the crystalline matrix of calcified plaque. Methods of treatment comprising applying the disclosed composition are also disclosed. Plaque-softening compounds are also disclosed.

The present application relates to dyes containing a naphthalimide core and their uses as fluorescent labels. These dyes may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

The present application relates to dyes containing a naphthalimide core and their uses as fluorescent labels. These dyes may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

Disclosed is a five-feature pharmacophore model of LPA.sub.2 receptor specific agonists. Compounds may be identified as agonists of the LPA.sub.2 receptor using the five-feature pharmacophore model.

A chemically amplified resist composition is provided which is excellent in LWR and resolution and can prevent a resist pattern from collapsing in far ultraviolet lithography and EUV lithography, an onium salt for use therein, and a pattern forming process using the resist composition. The chemically amplified resist composition includes an onium salt having the following formula (1).

##STR00001##

A chemically amplified resist composition is provided which is excellent in LWR and resolution and can prevent a resist pattern from collapsing in far ultraviolet lithography and EUV lithography, an onium salt for use therein, and a pattern forming process using the resist composition. The chemically amplified resist composition includes an onium salt having the following formula (1).

##STR00001##